Physicochemical stability of lurbinectedin reconstituted at 500 μg/mL and diluted at 15, 30, and 70 μg/mL in 0.9% sodium chloride and 5% dextrose-Reference-Cited by-同舟云学术

Physicochemical stability of lurbinectedin reconstituted at 500 μg/mL and diluted at 15, 30, and 70 μg/mL in 0.9% sodium chloride and 5% dextrose

Published:2021-07 Issue:3 Volume:4 Page:e032
ISSN:2032-7072
Container-title:European Journal of Oncology Pharmacy
language:en
Short-container-title:

Author:

Loeuille Guillaume,Vigneron Jean,D’Huart Elise,Demoré Béatrice

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology,Oncology

Reference5 articles.

1. ATLANTIS: a phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line;Farago;Future Oncol Lond Engl,2019

2. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial;Trigo;Lancet Oncol,2020

3. Physikalisch-chemische Stabilität von rekonstituierten Trabectedin-haltigen Lösungen. Weitergehende Überlegungen zur Haltbarkeit und Aufbrauchfrist;Lipp;Krankenhauspharmazie,2017

4. Guidelines for the practical stability studies of anticancer drugs: a European consensus conference;Bardin;Ann Pharm Fr,2011

5. Quantification of trabectedin in human plasma: validation of a high-performance liquid chromatography-mass spectrometry method and its application in a clinical pharmacokinetic study;Zangarini;J Pharm Biomed Anal,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physicochemical stability of pevonedistat at 50, 100 and 200 µg/mL diluted in 0.9% sodium chloride and at 10 mg/mL in partially used vials;European Journal of Hospital Pharmacy;2024-02-26